| Literature DB >> 35057797 |
Yongyan Shan1, Qian Wang1, Yitong Zhang1, Xuewei Tong1, Shengdan Pu1, Yuxin Xu1, Xinyuan Gao2.
Abstract
BACKGROUND: Diabetic retinopathy (DR) is the primary oculopathy causing blindness in diabetic patients. Currently, there is increasing interest in the role of lipids in the development of diabetic retinopathy, but it remains controversial. Remnant cholesterol (RC) is an inexpensive and easily measurable lipid parameter; however, the relationship between RC and DR in type 2 diabetes mellitus (T2DM) has not been elucidated. This research investigates the relevance between RC levels and DR severity while building a risk prediction model about DR.Entities:
Keywords: DME; Diabetic retinopathy; NLR; Nomogram; Remnant cholesterol; TyG-index; Type 2 diabetes mellitus
Mesh:
Substances:
Year: 2022 PMID: 35057797 PMCID: PMC8772129 DOI: 10.1186/s12944-021-01621-7
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Characteristics of the non-DR group and DR group
| Variables | All ( | Non-DR ( | DR ( | |
|---|---|---|---|---|
| Age (years) | 53.54 ± 12.13 / 55 (44–63) | 53 (40–62) | 57 (47–64) | 0.009** |
| Male gender, n (%) | 292 (64) | 161 (65.2) | 131 (62.7) | 0.579 |
| Diabetes duration (years) | 9.73 ± 6.97 / 9 (4–15) | 7 (3–12) | 11 (6–16) | 0.001** |
| Hypertension, n (%) | 232 (46.4) | 105 (42.5) | 127 (50.2) | 0.085 |
| Current smoking, n (%) | 150 (32.9) | 89 (36) | 61 (29.2) | 0.121 |
| DNP, n (%) | 175 (38.5) | 79 (33.2) | 96 (44.2) | 0.027 |
| BMI (kg/m2) | 25.6 (23.92–27.95) | 25.39 (23.84–27.39) | 25.6 (23.98–28.09) | 0.929 |
| SBP (mmHg) | 140 (126–150) | 137 (123–150) | 140 (130–154) | 0.007* |
| DBP (mmHg) | 80 (74–90) | 80 (72–88) | 81 (75–90) | 0.067 |
| FBG (mmol/L) | 8.44 (6.88–10.61) | 8.2 (6.79–10.54) | 8.59 (7.04–10.71) | 0.163 |
| HbA1c (%) | 8.4 (7.2–9.6) | 8.2 (7.1–9.5) | 8.5 (7.6–9.8) | 0.076 |
| HbA1c (mmol/mol) | 68 (55–81) | 66 (54–80) | 69 (60–84) | 0.057 |
| Fasting C-Peptide (ng/ml) | 1.5 (1.0–2.2) | 1.55 (1.0–2.3) | 1.5 (1.0–2.15) | 0.426 |
| Neutrophil (× 109/L) | 3.71 (3.05–4.45) | 3.48 (2.96–4.41) | 3.85 (3.17–4.5) | 0.01* |
| Lymphocyte (×109/L) | 2.22 (1.78–2.64) | 2.26 (1.87–2.69) | 2.17 (1.73–2.56) | 0.053 |
| Monocyte (×109/L) | 0.38 (0.31–0.45) | 0.38 (0.3–0.45) | 0.38 (0.31–0.44) | 0.31 |
| TC (mmol/L) | 5.02 (4.42–5.74) | 4.96 (4.24–5.58) | 5.13 (4.58–5.96) | 0.000** |
| TG (mmol/L) | 2.18 (1.4–3.43) | 2.12 (1.43–3.2) | 2.31 (1.35–3.59) | 0.286 |
| HDL-C (mmol/L) | 1.15 (0.99–1.3) | 1.11 (0.99–1.28) | 1.16 (1.00–1.325) | 0.496 |
| LDL-C (mmol/L) | 3.09 (2.66–3.58) | 3.14 (2.65–3.59) | 3.05 (2.66–3.55) | 0.822 |
| APOA (g/L) | 1.26 (1.13–1.39) | 1.25 (1.14–1.39) | 1.21 (1.11–1.40) | 0.981 |
| APOB (g/L) | 1.03 (0.87–1.21) | 1.035 (0.84–1.2) | 1.03 (0.9–1.22) | 0.2 |
| RC (mmol/L) | 0.65 (0.45–0.99) | 0.54 (0.31–0.83) | 0.74 (0.60–1.12) | 0.000** |
| TyG-index | 9.62 ± 0.78 | 9.52 ± 0.73 | 9.72 ± 0.82 | 0.006* |
| NLR | 1.64 (1.36–2.03) | 1.60 (1.30–1.93) | 1.69 (1.41–2.26) | 0.000** |
| Uric Acid (μmol/L) | 329.3 (280.4–393.8) | 326.3 (276.6–395) | 330.8 (286.05–393.7) | 0.644 |
| Creatinine (μmol/L) | 61.3 (50.6–70.5) | 60.5 (50.45–70.13) | 62.3 (51.1–72.4) | 0.384 |
| eGFR (ml/min/1.73m2) | 108.6 (97.68–121.03) | 110.96 (98.24–123.10) | 106.27 (96–117.95) | 0.013 |
| mAlb (mg/24 h) | 20.31 (19.76–33.63) | 19.95 (19.57–23.56) | 20.71 (19.95–56.53) | 0.000** |
| Metformin, n (%) | 277 (60.7) | 149 (60.3) | 128 (61.2) | 0.841 |
| DPP-IV inhibitor, n (%) | 189 (41.4) | 98 (39.7) | 91 (43.5) | 0.404 |
| Acarbose, n (%) | 68 (15.3) | 38 (15.9) | 30 (14.6) | 0.712 |
| Insulin, n (%) | 139 (30.5) | 72 (29.1) | 67 (32.1) | 0.502 |
| Anitihypertensive drugs, n (%) | 159 (34.9) | 76 (30.8) | 83 (39.7) | 0.046* |
Abbreviations: DR diabetic retinopathy, DPN diabetic peripheral neuropathy, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, FBG Fasting blood glucose, APOA apolipoprotein A, APOB apolipoprotein B, TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, RC remnant cholesterol, eGFR estimated glomerular filtration rate, HbA1c glycosylated hemoglobin, TyG-index triglyceride glucose index, NLR neutrophil to lymphocyte ratio, DR diabetic retinopathy, DPP-IV dipeptidyl peptidase-IV, mAlb microalbuminuria
Notes: Data are expressed as mean ± SD, percentages, or as medians (IQR); p-values were compared by independent t-test, Mann-Whitney U test, or Chi-square test as appropriate.*P < 0.05, **P < 0. 001
The correlation between stages of DR and the following lipid profiles
| Variables | Spearman Correlation Analysis | Partial Correlation Analysis | ||
|---|---|---|---|---|
| r | r | |||
| RC (mmol/L) | 0.360 | 0.000** | – | – |
| TC (mmol/L) | 0.142 | 0.002* | 0.289a | 0.000** |
| TG (mmol/L) | 0.068 | 0.148 | 0.324b | 0.000** |
| LDL-C (mmol/L) | −0.016 | 0.736 | 0.332c | 0.000** |
| HDL-C (mmol/L) | 0.054 | 0.254 | 0.327d | 0.000** |
| APOA (g/L) | 0.003 | 0.947 | 0.334e | 0.000** |
| APOB (g/L) | 0.066 | 0.165 | 0.329f | 0.000** |
Abbreviations: APOA apolipoprotein A, APOB apolipoprotein B, RC Remnant cholesterol, TC total cholesterol, TG triglycerides, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, APOA apolipoprotein A, APOB apolipoprotein B
Notes: associations between serum lipid profile and stages of DR by Spearman correlation analysis and the association between RC and stages of DR by partial correlation analysis aAdjusted for TC; bAdjusted for TG; cAdjusted for LDL-C; dAdjusted for HDL; eAdjusted for APOA; fAdjusted for APOB. *P < 0.05, **P < 0. 001
The association between RC value and DR
| Factors | Univariate model | Multivariate model | ||||
|---|---|---|---|---|---|---|
| OR | 95%CI | OR | 95%CI | |||
| Age, per10y increase | 1.221 | 1.051–1.418 | 0.009** | 1.002 | 0.981–1.022 | 0.880 |
| Diabetes duration, per 1y increase | 1.357 | 1.184–1.555 | 0.000** | 1.072 | 1.036–1.110 | 0.000** |
| DPN, yes or no | 1.561 | 1.067–2.284 | 0.022 | 1.201 | 0.770–1.873 | 0.419 |
| Anitihypertensive drugs, yes or no | 0.6 | 0.458–0.994 | 0.046 | 1.062 | 0.666–1.690 | 0.800 |
| SBP, per10mmHg increase | 1.16 | 1.043–1.289 | 0.006* | 1.004 | 0.992–1.018 | 0.498 |
| FBG, per 1 mmol/L increase | 1.04 | 0.976–1.108 | 0.228 | |||
| HbA1c per1% increase | 1.078 | 0.971–1.197 | 0.159 | |||
| Uric acid per 1 μmol/l increase | 1.00 | 0.998–1.001 | 0.61 | |||
| TC, per 1 mmol/L increase | 1.367 | 1.145–1.632 | 0.000** | 0.936 | 0.731–1.198 | 0.598 |
| TG, per 1 mmol/L increase | 1.087 | 0.995–1.187 | 0.064 | |||
| HDL-C, per 1 mmol/L increase | 1.315 | 0.676–2.556 | 0.42 | |||
| LDL-C, per 1 mmol/L increase | 1.007 | 0.793–1.279 | 0.956 | |||
| eGFR, per10-1-1 (ml/min/1.73m2) increase | 0.93 | 0.844–1.026 | 0.147 | |||
| mAlb > 30 mg/24 h, yes or no | 1.003 | 1.001–1.005 | 0.003* | 1.334 | 0.814–2.185 | 0.252 |
| TyG-index per1 increase | 1.393 | 1.095–1.772 | 0.007 | 0.766 | 0.554–1.059 | 0.106 |
| RC, per 1 mmol/L increase | 6.823 | 4.011–11.609 | 0.000** | 5.623 | 2.996–10.556 | 0.000** |
| NLR per1 increase | 1.801 | 1.310–2.477 | 0.000** | 1.598 | 1.121–2.279 | 0.01* |
Abbreviations: DR diabetic retinopathy, DPN diabetic peripheral neuropathy, BMI body mass index, SBP systolic blood pressure, FBG Fasting blood glucose, HbA1c glycosylated hemoglobin, TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, APOA apolipoprotein A, APOB apolipoprotein B, eGFR estimated glomerular filtration rate, TyG-index triglyceride glucose index, SBP systolic blood pressure, UA Uric acid, NLR Neutrophil–Lymphocyte ratio, TyG-index triglyceride glucose index, mAlb microalbuminuria
Notes: Binary Logistic Regression Analysis.*P < 0.05, **P < 0. 001
Fig. 1Nomogram showed the risk of DR. Abbreviations: DR: diabetic retinopathy; RC: remnant cholesterol; NLR: neutrophil-lymphocyte ratio
Fig. 2The relationship between RC levels and DR, stages of DR, and DME. Abbreviations: DR: diabetic retinopathy; NPDR: non-proliferative diabetic retinopathy; PDR: proliferative diabetic retinopathy; DME: diabetic macular edema. Notes: The RC level was divided into three groups by tertile, Tertile1 group (< 0.52 mmol/l, N = 150), Tertile2 group (0.52–0.83mmo/l, N = 152) and Tertile3 group (> 0.83 mmol/l, N = 154). Chi-square test was used for comparison between groups, *P < 0.05, **P < 0. 01
The correlation between RC value and other potential risk factors of DR
| Variables | Spearman Correlation Analysis | |
|---|---|---|
| r | ||
| Age (years) | −0.007 | 0.884 |
| Diabetes duration (years) | 0.068 | 0.149 |
| BMI (kg/m2) | 0.104 | 0.027* |
| Fasting C-pepide (ng/ml) | 0.007 | 0.885 |
| HbA1c (%) | 0.101 | 0.031* |
| TC (mmol/L) | 0.559 | 0.000** |
| TG (mmol/L) | 0.447 | 0.000** |
| HDL-C (mmol/L) | 0.085 | 0.069 |
| LDL-C (mmol/L) | 0.136 | 0.002* |
| APOA (g/L) | 0.033 | 0.49 |
| APOB (g/L) | 0.398 | 0.000* |
| eGFR (ml/min/1.73m2) | −0.004 | 0.927 |
| UA (μmol/L) | 0.15 | 0.000** |
| mAlb (mg/24 h) | 0.179 | 0.000** |
| NLR | 0.035 | 0.463 |
| TyG-index | 0.488 | 0.000** |
Abbreviations: DR diabetic retinopathy, BMI body mass index, HbA1c glycated hemoglobin, TC total cholesterol, TG triglyceride, HDL high-density lipoprotein, LDL low-density lipoprotein, APOA apolipoprotein A, APOB apolipoprotein B, eGFR estimated glomerular filtration rate, TyG-index triglyceride glucose index, UA Uric Acid, NLR Neutrophil–Lymphocyte ratio, TyG-index triglyceride glucose index, mAlb microalbuminuria
Notes: Spearman Correlation Analysis. *P < 0.05, **P < 0. 001